Market closed
MeiraGTx/$MGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
389
Website
MeiraGTx Metrics
BasicAdvanced
$501M
-
-$1.34
1.25
-
Price and volume
Market cap
$501M
Beta
1.25
52-week high
$7.80
52-week low
$3.85
Average daily volume
316K
Financial strength
Current ratio
2.34
Quick ratio
2.21
Long term debt to equity
86.229
Total debt to equity
90.598
Interest coverage (TTM)
-13.26%
Management effectiveness
Return on assets (TTM)
-38.93%
Return on equity (TTM)
-93.99%
Valuation
Price to revenue (TTM)
30.193
Price to book
5.2
Price to tangible book (TTM)
5.25
Price to free cash flow (TTM)
-4.102
Growth
Revenue change (TTM)
108.24%
Earnings per share change (TTM)
-46.24%
3-year revenue growth (CAGR)
-12.01%
3-year earnings per share growth (CAGR)
-10.29%
What the Analysts think about MeiraGTx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
MeiraGTx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MeiraGTx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MeiraGTx News
AllArticlesVideos
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
GlobeNewsWire·10 hours ago
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process
GlobeNewsWire·10 hours ago
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $501M as of March 13, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of March 13, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.